RxDoctor Payments Data

Rohit Parihar, MD

Ophthalmology · Melbourne, FLNPI 1912134818

Payments from drug & device makers

$932in general payments, 2019–2025

Across 38 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$278
  • Alcon$191
  • Eyepoint US, Inc.$106
  • Johnson & Johnson Surgical Vision, Inc.$80
  • Bausch & Lomb Americas Inc.$68
  • Oyster Point Pharma, Inc.$49
  • plus $162 from 6 others

What the payments were for

  • Consulting fees$384%
  • Food & beverage$89496%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$932 in reported general payments places this provider in the 30th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$480,936
Medicare patients
1,271
Services billed
3,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine69$66,699
XiidraLifitegrast34$25,549
LumiganBimatoprost37$15,638
Latanoprost1,148$15,561
Prednisolone Acetate370$11,800
IlevroNepafenac27$10,121
Fluorometholone152$9,107
RocklatanNetarsudil Mesylat/Latanoprost17$6,904
Timolol Maleate302$6,024
RhopressaNetarsudil Mesylate13$5,760
Cyclosporine13$5,652
Difluprednate48$5,227
ErythromycinErythromycin Base467$5,222
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$4,202
VyzultaLatanoprostene Bunod14$3,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$278$85,083120 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$68$29,33248 claims
AlconSimbrinza$191$3,31018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →